- Home
- GRFS vs CZR Comparison
GRFS vs CZR Comparison
Compare GRFS & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRFS | CZR |
|---|---|---|
| Founded | 1940 | 1937 |
| Country | Spain | United States |
| Employees | 25247 | 15500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GRFS | CZR |
|---|---|---|
| Price | $7.64 | $29.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $10.15 | ★ $31.92 |
| AVG Volume (30 Days) | 569.0K | ★ 9.5M |
| Earning Date | 07-28-2022 | 04-28-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,473,504,000.00 |
| Revenue This Year | $4.49 | $3.56 |
| Revenue Next Year | $6.42 | $2.48 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | ★ 65.03 |
| 52 Week Low | $7.26 | $17.86 |
| 52 Week High | $11.14 | $31.58 |
Technical Indicators
Market Signals| Indicator | GRFS | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 66.69 |
| Support Level | $7.64 | $27.22 |
| Resistance Level | $8.24 | $30.88 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 44.02 | 93.72 |
Price Performance
Historical ComparisonAbout GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
About CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.